DuPont Nutrition & Biosciences recently released the findings of a first-time new study showing the effects Care4U™ 2’-FL had on dental caries-associated bacterium Streptococcus mutans. Previously, HMOs have not been studied for their effects on oral bacteria, but as HMOs are increasingly being added to infant formula, it is important to evaluate effects on oral microflora and potential impact on oral health.
Regulatory Update: Our New HMO, 3-FL
In addition to the exciting research being conducted on Care4U™ 2’-FL, DuPont recognizes the need to continue to bridge the nutritional gap in infant formula. The next most abundant HMO in human milk after 2’-FL, and soon to be commercialized by DuPont, is 3-fucosyllactose (3-FL). This HMO is present in human milk of all mothers and is unique in that levels have been reported to increase during lactation, contrary to 2’FL that decreases during lactation. Initial in vitro research demonstrates that in addition to being bifidogenic, this HMO is effective in reducing colon motor contractions and inhibits bacterial adhesion. Further research is needed to confirm clinical benefits.
A scientific expert panel has recently concluded that DuPont’s newest HMO, Care4U™ 3-FL HMO, is Generally Recognized as Safe (GRAS) for use in various applications including formulas intended for infants and young children, other foods and beverages consumed by toddlers under 3 years as well as foods for the general population. The FDA has been notified of DuPont’s GRAS conclusion. In October 2019, DuPont submitted a novel food application with the European Food Safety Authority (EFSA) to obtain market authorization in the EU for 3-FL. These regulatory developments demonstrate the steady progression of DuPont’s investment and commitment to HMOs.
DOWNLOAD THE INFOGRAPHIC: LINK